Sotyktu (deucravacitinib) sought the efficacy of a JAK inhibitor in psoriasis without inheriting the class-wide safety warnings that limit their use.
Deucravacitinib binds a regulatory pseudokinase domain rather than the active site, selectively blocking IL-23 and interferon signaling as the first allosteric TYK2 inhibitor. The once-daily tablet treats adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
That allosteric selectivity is why Sotyktu carries no JAK class boxed warning, which is its central commercial argument against oral competitors. With no generic competition, its expansion into psoriatic arthritis and other immunology indications is the key value driver to follow.
